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Abstract
Mucinous breast cancer (MBC) is mainly a disease of postmenopausal women. Pure MBC is rare
and augurs a good prognosis. In contrast, MBC mixed with other histological subtypes of invasive
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disease loses the more favorable prognosis. Because of the relative rarity of pure MBC, little is
known about its cell and tumor biology and relationship to invasive disease of other subtypes. We
have now developed a human breast cancer cell line called BCK4, in which we can control the
behavior of MBC. BCK4 cells were derived from a patient whose poorly differentiated primary
tumor was treated with chemotherapy, radiation and tamoxifen. Malignant cells from a recurrent
pleural effusion were xenografted in mammary glands of a nude mouse. Cells from the solid
tumor xenograft were propagated in culture to generate the BCK4 cell line. Multiple marker and
chromosome analyses demonstrate that BCK4 cells are human, near diploid and luminal,
expressing functional estrogen, androgen, and progesterone receptors. When xenografted back into
immunocompromised cycling mice, BCK4 cells grow into small pure MBC. However, if mice are
supplemented with continuous estradiol, tumors switch to invasive lobular carcinoma (ILC) with
mucinous features (mixed MBC), and growth is markedly accelerated. Tamoxifen prevents the
expansion of this more invasive component. The unexpected ability of estrogens to convert pure
MBC into mixed MBC with ILC may explain the rarity of the pure disease in premenopausal
women. These studies show that MBC can be derived from lobular precursors and that BCK4 cells
are new, unique models to study the phenotypic plasticity, hormonal regulation, optimal
therapeutic interventions, and metastatic patterns of MBC.
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Introduction
Most invasive breast cancers are categorized as ductal (IDC), lobular (ILC), or a mixture of
the two, but distinguishing among these can be challenging. Fifty to 80 % of breast cancers
are classified as IDC “not otherwise specified” (IDC NOS) [1]. ILC comprise only 3–14 %
of invasive breast cancers [2–5]. The incidence of ILC has increased over the past 20 years
in women over 50 [6] potentially due to use of hormone replacement therapy [7, 8].
Compared to IDC, ILC occurs in older women and tends to be (1) larger at diagnosis; (2)
estrogen receptor (ER) positive; (3) more differentiated; and (4) less vascularized [9].
Molecular discriminators between ILC and IDC include the lack of E-cadherin and positive
cytoplasmic expression of delta catenin (p120 catenin) in ILC. Expression profiling has been
performed to define markers unique to ILC and IDC [10–13] but the only common
discriminator between the two tumor types appears to be loss of E-cadherin. Nevertheless,
loss of E-cadherin alone is not sufficient to define ILC, as ~15 % of IDC also lack E-
cadherin [14].
Among all breast cancers, 25 % contain phenotypic markers that allow sub-classification
into rarer subtypes including apocrine, sebaceous, tubular, and mucinous breast cancers
(MBC; also called colloidal or gelatinous). The definition of MBC is complex [1]. The
World Health Organization does not recognize mucinous components if the non-mucinous
invasive disease exceeds 50 %. If the non-mucinous component falls to 10–49 % then
tumors are classified as “mixed,” and if the non-mucinous component is <10 % tumors are
defined as “pure” MBC. The Royal College of Pathologists definition is similar; to be
classified as pure MBC, ≥90 % of the tumor must be composed of epithelial cells floating in
“a sea of” mucin [15].
The origin of “pure” and “mixed” MBC is unclear. Ductal versus mixed MBC is now
largely referred to as a subtype of IDC, most often called “IDC with mucinous features”
[16]. This is based on the assumption that extracellular mucin production is most often
associated with IDC [1], despite the fact that ILC can also produce extracellular mucin [17–
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19]. Intracellular mucin production and/or signet ring cells are typically associated with an
invasive component characteristic of ILC [5, 20–23]. However, in rare cases signet ring cells
are associated with a variant of ductal carcinoma in situ [24] resembling diffuse gastric
carcinomas [1]. Thus in mucinous disease, the distinctions between ILC and IDC remain
unclear. The studies we describe here address these issues. Under current definitions,
approximately 7 % of breast cancers in women over 75 years of age [25], and <1 % in
women under 35, are classified as MBC; the overall rate is estimated to be 2–4 %. Because
no clear definition of pure versus mixed MBC is used uniformly, their percent of all breast
cancers is likely to be underestimated.
MBC are generally luminal-type tumors that are ER, progesterone (PR), and androgen (AR)
receptor-positive, without HER2 overexpression and with a low S-phase fraction [26, 27].
Excessive extracellular mucin secretion is observed, but external lamina or basement
membranes are not detected [28]. While mucin 1 (Muc1) is aberrantly overexpressed in ~90
% of all breast cancers [29], Muc2—a gel-forming secretory mucin expressed in the
cytoplasm of pure and mixed MBC cases [30]—is not found in ILC and rarely in IDC [31],
making it a good marker for mucinous components of all breast cancers. A diagnosis of
MBC augurs a good prognosis with low probability of immediate metastasis [26]. However,
both pure and mixed MBC can and do metastasize [32–37] with a propensity for late
recurrences [35]. Invasive MBC has been diagnosed in association with ductal carcinoma in
situ [38, 39] where it reportedly induces hyper-vascularization [39].
Cell lines are important models for studies of human breast cancer because they faithfully
recapitulate gene expression patterns of tumors taken from patients [40]. Virtually all breast
cancer lines currently in use are models of IDC, and ER+ cell lines that constitutively
express PR protein in the absence of estradiol are rare. Models of ILC are also rare. To our
knowledge only four—SUM44, MDA-MB-134 VI, IPH-926, and HCC2185—have been
described, perhaps reflecting the rarity of this histologic subtype.
To date, no MBC cell lines exist of either the pure or mixed subtype. Here we report
development of such a cell line we call “BCK4.” It was derived from a breast cancer patient
who presented with a lymph node-positive, poorly differentiated adenocarcinoma. Her
primary tumor was ER+, with PR and HER2 unknown. Following tumor resection, she
received chemotherapy, radiation, and 5 years of tamoxifen. Three years later she was
diagnosed with a recurrent pleural effusion and underwent therapeutic thoracentesis. BCK4
cells were developed from the pleural effusion. The cells are steroid receptor-positive,
contain luminal cytokeratins, are of lobular origin, and grow into pure MBC when
xenografted in the mammary glands of immunocompromised cycling mice. However, tumor
growth is markedly accelerated and the phenotype switches to mixed MBC if mice are
supplemented with continuous estradiol (E2). We propose that this effect of estrogens
explains the rarity of pure MBC in premenopausal women and provides a mechanism
through which estrogen-containing hormone replacement therapy stimulates the growth and
progression of ILC. This new model will be extremely useful in studies of the molecular and
tumor biology of MBC.
Materials and methods
Clinical background
The patient, a 65-year-old female, presented with a 3 cm, poorly differentiated
adenocarcinoma with involved lymph nodes. The tumor was ER+; PR and HER2 status
were unknown. After resection she received six cycles of cyclophosphamide, doxorubicin,
and 5-fluorouracil, followed by radiation therapy and 5 years of tamoxifen. Three years after
completing tamoxifen she presented with a malignant pleural effusion and underwent
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therapeutic thoracentesis. Immunocytochemical staining of the pleural cells showed them to
be negative for ER (0 %) and HER2 (0 %) with focal PR expression (7 %). An Institutional
Review Board approved the tissue acquisition protocol and patient-informed consent was
obtained to acquire blood and tissue for research purposes.
Mouse explants of primary tumor cells and BCK4 development
All animal studies were performed according to a protocol approved by the University of
Colorado Institutional Animal Care and Use Committee. Cells from the pleural effusion
were transferred to flasks for 4 days to remove blood cells and other debris, then injected
into mammary glands of ovariectomized nude mice supplemented with 17-beta-estradiol
(E2) as described [41]. Tumors were grown for 12 weeks. Tumor xenografts were resected
and cells were mechanically dispersed using a wire gauze and glass pestle. Cells were
seeded into 6 well dishes, allowed to adhere and grown at 37 °C under 5 % CO2 in
minimum essential medium (MEM) with Earle’s salts containing L-glutamine (292 µg/l)
buffered with sodium bicarbonate (2.2 µg/l), insulin (6 ng/ml), non-essential amino acids (10
mM), and 5 % fetal calf serum. Cells were fed every 3–4 days. After ~14 months a stable
cell line emerged, which was characterized and named BCK4. Short tandem repeat analysis
performed at the University of Colorado Cancer Center Sequencing Core confirmed the
human and unique genetic properties of the BCK4 cell line.
ZsGreen labeling of cells
BCK4 cells plated in a T75 flask were incubated with 15 ml of a retroviral vector encoding
ZsGreen produced by Amphopack-293 cells (Clontech). Cells were transduced twice more
and selected with G418. Green fluorescent cells were expanded and sorted for the brightest
10 % using a MoFlow cytometer as described [41].
BCK4 xenografts
ZsGreen-tagged BCK4 cells (5 × 106) in Matrigel were injected bilaterally into the 4th
mammary glands of nonovariectomized NOD/SCID mice that had been implanted
subcutaneously with a cellulose or E2-releasing pellet [41]. Tumors were grown for 22
weeks. Mice were injected intraperitoneally 2 h before sacrifice with 10 mg/kg of
Bromodeoxyuridine (BrdU).
Three-dimensional (3D) assays
BCK4 cells (2 × 105) were plated onto Matrigel and treated with hormones. Colonies were
paraffin embedded and sectioned as previously described [42] and stained with hematoxylin
and eosin (H&E). Slides were imaged using a Nikon Eclipse E600 microscope (Nikon
Corporation) coupled to an RGB-MS-C MicroColor camera (CRI, Inc.). Quantification of at
least five fields and two wells per condition were performed to assess signet ring cell
formation using Image Pro Plus 4.5 software (Media Cybernetics).
Immunocytochemistry (ICC) and antibodies
BCK4 cells were plated onto coverslips, fixed and ICC was performed as described [41].
Antibodies were: ER (Neomarkers, SP1) 1:100, PR (DAKO, 1294) 1:500, AR (Upstate,
PG-21) 1:35, BrdU (BD Biosciences) 1:50, Her2 (Neomarkers, SP3) 1:50, CK5
(Novacastra, XM26) 1:100, CD10 (Epitomics, EP2998) 1:100, CK14 (Neomarkers) 1:200,
CK18 (Calbiochem) 1:400, CK8/18 (Novocastra, 5D3) 1:100, CD117 (DAKO) 1:400, CD44
(Neomarkers 156-3C11) 1:200, EGFR (Epitomics E114) 1:12, E-Cadherin (DAKO) 1:25,
p63 (Epitomics Y289) 1:250, Mammaglobin A (Abcam, 304-1A5) prediluted,
Chromograinin A (Abcam) 1:60, Synaptophysin (Abcam) 1:100, Vimentin (Epitomics,
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SP20) 1:200, Vimentin (Abcam, V9) 1:50, α-SMA (Epitomics, E184) 1:400, p120 catenin
(Epitomics, #2806) 1:250.
Immunohistochemistry (IHC)
IHC of paraffin sections was performed as described [41] using the antibodies above, plus
an antibody to Muc2 (ab37433, Abcam) 1:200. Tumors were dual stained using DAB (ER,
PR) and AP-conjugated permanent red (CK8/18) as previously described [43]. ZsGreen was
visualized in paraffin sections as described [41]. BrdU labeling of paraffin sections and
quantification of mitotic cells were performed as described [42]. Paraffin sections were
stained for mucin using EZ Mucicarmine dye (Anatech Ltd.) and EZ Green (Anatech Ltd.)
to counterstain nuclei according to the manufacturer’s instructions.
Microscopy
Whole tumor micrographs were scanned with a Nikon Eclipse Ti inverted microscope using
Nikon Instruments Software Elements and a Nikon ss-Fi1 camera for bright-field images or
a Nikon Ds-Qi1MC camera for fluorescent images.
Karyotyping/SKY
Karyotyping/SKY was performed by the University of Colorado Cancer Center
Cytogenetics Core as described [44]. Image acquisition used a SD300 Spectracube system
(ASI) mounted in an Olympus BX60 microscope with a custom-designed optical filter
(SKY-1, Chroma Technology). Conversion of the emission spectra to the display colors was
achieved by assigning blue, green, and red to specific sections of the emission spectrum.
RT-PCR
Total RNA was prepared using the Qiagen mini kit as directed. RNA was reverse
transcribed into cDNA using MULV reverse transcriptase as described [45]. Primers were:
FKBP5 [45]; SGK (SGK1) [46]; DUSP1 fwd 5′-TT TGAGGGTCACTACCAG-3′, DUSP1
rev 5′-GAGATGA TGCTTCGCC-3′; HSD11B2 primers [45]; GAPDH primers [45]; pS2
fwd 5′-TTTGGAGCAGAGAGGAGGCAAT GG-3′, pS2 rev 5′-
TGGTATTAGGATAGAAGCACCAG GG-3′; CathD fwd 5′-
GTGCTTCACAGTCGTCTTC-3′, CathD rev 5′-GAGCCATAGTGGATGTCAAAC-3′.
Semi-quantitative PCR was performed as described [45].
MTS assay
10,000 cells/well were plated into a 96 well plate and grown overnight. Cells were changed
into phenol-red free MEM + steroid depleted serum with vehicle or hormone treatments (10
nM). MTS assays were performed using the Cell Titer 96 Aqueous One Solution Cell
Proliferation Assay (Promega) according to the manufacturer’s instructions. Absorbance
was measured at 490 nm.
Transcription
Transfections used (PR) PRE2- and (ER) ERE2-luciferase/ promoters containing hormone
response elements coupled to reporter constructs as previously described [46]. They were
electroporated into 2.4 × 106 BCK4 cells in 4 cm cuvettes at 275 V. Transfected cells were
treated with vehicle or hormones for 24 h, harvested, and luciferase assays were performed
as described [46].
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Generation of the BCK4 cell line
Cells from the pleural effusion of a breast cancer patient were explanted bilaterally into the
4th mammary glands of an immunocompromised, ovariectomized mouse [41]. First
generation tumors were formed and were resected. One was fixed and stained by IHC; the
other was mechanically dispersed and cultured as described in “Materials and methods”
section. Two novel stable and permanent lines were established from the dispersed cells: a
mouse mammary stromal cell line, BJ3Z described previously [41], and a human breast
cancer cell line named BCK4 described herein.
IHC characterization of the patient explant
One xenografted tumor derived directly from the patient’s cells was fixed, paraffin
embedded, sectioned, and stained with H&E or used for IHC (Fig. 1; Table 1). The
xenograft was characteristic of an invasive adenocarcinoma with mucinous features. It was
luminal as indicated by expression of ER, PR, and AR (Fig. 1); by cytokeratin (CK) 8/18
positivity (not shown); and by the absence of the basal markers, epidermal growth factor
receptor (EGFR) and CK5 (not shown). The xenograft stained weakly for HER2 (Fig. 1) but
quantification of this oncogene by FISH (not shown) indicated that it was not overexpressed.
Xenografted cells also expressed CD44 (Fig. 1), a marker often associated with tumor
initiating cells. The change in ER status of the xenograft tumor (ER+) compared to the
patient’s pleural effusion (ER−) likely reflects technical artifacts in the clinical sample such
as the small sample size used to measure ER and contamination of the effusion with normal
lung epithelial cells.
Characterization of the BCK4 cell line
We have extensively characterized the BCK4 cell line that grew out of the xenograft of the
patient’s pleural effusion.
Karyotype—Metaphase chromosomes of BCK4 cells were analyzed by GTL banding (not
shown) and Spectral Karyotyping (SKY) to assign their species of origin, define a modal
chromosome number, and identify anomalies, if any (Fig. 2). The composite SKY karyotype
shows 21 diploid and 1 triploid (chr17) chromosome, plus diploid X chromosomes
demonstrating that the BCK4 cells are human, female, and relatively normal. The formal
description—47,XX,del(1) (?p31;?q12),del(7)(q22),der(8)t(8;11)(p11;q13),11,der(16)
t(1;16)(q12;q11.2)×2,+17—contains few anomalies. The BCK4 karyotype is much closer to
normal than that of the commonly used T47D or MCF7 human breast cancer cells, which
like 58 % of IDC with mucinous features [47] are aneuploid. The normality of BCK4 cells
concurs with the observation that 96 % of pure MBC have diploid DNA by flow cytometry
[47]. The karyotype of BCK4 cells is the first for any MBC. Importantly, the karyotype of
the BCK4 cells is nearly identical to the karyotype of the original cells derived from the
pleural effusion of the patient (Supplementary Fig. 1). Additionally, single tandem repeat
analysis of the patient’s pleural effusion cells matched the BCK4 cell line (not shown).
Protein expression—To further characterize BCK4 cells, key biomarkers were analyzed
by ICC, immunoblotting, and IHC (Supplementary Fig. 2; Table 1). Like the patient’s tumor
explant, the BCK4 cell line is ER, PR, and AR-positive (Supplementary Fig. 2); ER and PR
levels are similar to those in T47D cells, but AR levels are higher. Table 1 shows IHC semi-
quantification for other markers. BCK4 cells weakly express Her2 protein but the HER2
gene is not overexpressed (not shown). The BCK4 cells are glucocorticoid receptor (GR)-
positive and strongly express the epithelial and luminal specific marker CK8/18, but lack the
basal markers vimentin, CK5 and CK14, putting these cells in the luminal category.
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Interestingly, the BCK4 cells lack E-cadherin and contain cytoplasmic/nuclear p120 catenin.
This combination is indicative of lobular carcinomas [17] and is discussed further below.
The patient explant contained less than 1.0 % E-cadherin positive cells, perhaps indicating
that it was of a mixed lobular/ductal phenotype. If so, we speculate that the BCK4 cell line
was generated from the lobular subpopulation.
Mucin producing breast cancers are often subclassified among neuroendocrine tumors [48],
and indeed, BCK4 cells express chromogranin A and synaptophysin which are characteristic
of such tumors (Table 1). Expression of mammaglobin-a (MAM-A) in BCK4 cells confirms
their breast origin. They also express the tyrosine kinase receptor and proto-oncogene c-kit
(CD117), which is a product of normal and benign breast tissues, but is often lost in breast
cancers [49]. Unlike the patient xenograft, BCK4 cells express low levels of the putative
tumor initiator cell marker CD44. Interestingly, BCK4 cells strongly express the
myoepithelial markers CD10, p63, and α-smooth muscle actin (αSMA), which confer a
poor prognosis to breast cancers regardless of ER or lymph node status [50], but may
provide clues about the cells of origin in MBC.
Steroid receptor function—To determine whether the steroid receptors in BCK4 cells
are functional, transcriptional and gene expression studies were performed. The ability of
the endogenous receptors to regulate transcription was tested by transfecting BCK4 cells
with a luciferase reporter driven by two copies of the cognate response element for PR, AR,
or GR (here called progesterone response element; PRE2) or for ER (estrogen response
element; ERE2). The transfected cells were then treated with ethanol control (EtOH) or the
appropriate hormones for 24 h (Fig. 3a). The synthetic progestins R5020 (10 nM) or
medroxyprogesterone acetate (MPA; 10 nM) stimulated PR-dependent PRE2 transcription
9.0- and 10.5-fold, respectively. AR-dependent transcription increased ~sevenfold in
response to the synthetic AR, R1881 (10 nM). ER are also functional since estradiol (E2, 10
nM) stimulated transcription from the ERE2 reporter ~sixfold (Fig. 3a). Interestingly,
despite the presence of GR proteins (not shown) and regardless of dose (1–1,000 nM), the
glucocorticoid dexamethasone failed to stimulate transcription from the PRE2 promoter
(Fig. 3a), or from an alternate canonical GR-dependent reporter driven by the mouse
mammary tumor virus (MMTV) long terminal repeat (LTR; not shown). However, BCK4
cells transfected with an exogenous wild-type GR expression vector supported transcription
from both PRE2 and MMTV response elements (not shown). This suggests that the cells
harbor a flaw in endogenous GR protein(s) or that smaller inhibitory isoforms of GR
predominate, but that the GR transcriptional machinery is functional.
The ability of steroid receptors in BCK4 cells to regulate endogenous genes was tested by
RT-PCR of several transcripts previously identified as steroid regulated in breast cancer cell
lines [45, 51, 52]. Figure 3b shows that FK506 binding protein 5 (FKBP5), serum/
glucocorticoid regulated kinase 1 (SGK1), dual specificity phosphatase 1 (DUSP1), and
hydroxysteroid (11-beta) dehydrogenase 2 (HSD11B2) are all upregulated by 6 or 24 h of
progestin or AR treatments, demonstrating again that PR and AR are functional. In contrast,
as with the exogenous reporters, 6 or 24 h of dexamethasone failed to regulate GR
responsive genes endogenously. Two classical ER regulated genes, pS2 and Cathepsin D
(CathD), were upregulated by 6 and 24 h treatment with E2 (Fig. 3b, right panel).
Proliferation—Cell growth was measured by MTS uptake in viable cells. The basal
doubling time of BCK4 cells is 4–5 days (~120 h; Fig. 3c, ethanol); much slower than that
of other breast cancer cell lines, which tend to double in 24–48 h [53]. However, BCK4 cell
growth is accelerated by the synthetic AR R1881, the mixed AR/progestin/glucocorti-coid
MPA, and by E2. On the other hand, proliferation via PR appears to be inhibited by the pure
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synthetic progestin R5020 (Fig. 3c) suggesting that the MPA proliferative effect is mediated
by AR, since the GR are non-functional.
BCK4 tumor xenografts
BCK4 cells were tumorigenic in immunocompromised mice. ZsGreen-tagged BCK4 cells
were implanted bilaterally into the 4th mammary glands of ovariectomized (not shown) or
intact immunocompromised mice, supplemented with placebo or E2-releasing pellets (Fig.
4) which raise circulating estrogen levels and render animals acyclic.
Tumorgenicity and effects of E2—BCK4 tumor growth was absolutely estrogen-
dependent in ovariectomized mice (not shown). In normal cycling mice (placebo) only small
tumors developed as shown by the cross section of a whole tumor (Fig. 4, left). In contrast,
much larger (~sixfold) tumors formed if mice were continuously supplemented with E2
(Fig. 4, right). To identify mucinous components, paraffin sections were stained with
mucicarmine (pink) and nuclei were counterstained green (Fig. 4). While the small tumors
of placebo mice were pure MBC (MBCPure) composed entirely of cells floating in mucin
(arrowhead), the much larger tumors derived from E2 supplemented mice were
characteristic of an invasive breast carcinoma (long arrow) with mucinous features
(arrowhead) (MBCMixed). These data demonstrate a heretofore unknown role for estrogens
in breast cancers, namely their ability to switch MBCPure into MBCMixed that is more
aggressive. The clinical implications are important because our model uses E2 levels that are
physiologic [54] and observed in women taking HRT [55].
Ductal or lobular carcinoma?—We next attempted to define whether the BCK4-
derived tumors are of ductal (IDC) or lobular (ILC) origin, based on H&E and mucin
staining. The slides were reviewed by a surgical pathologist. Figure 5 shows H&E (panel a)
and mucicarmine (panel b) stains of a tumor from a placebo mouse. This tumor contains
extracellular pools of mucin (panel b, black arrowhead), as well as intracellular mucin
characterized by the presence of signet ring cells (yellow arrowhead). Collectively, the
pathology is consistent with a diagnosis of MBCPure.
In contrast, tumors from an E2 supplemented mouse are heterogeneous, containing areas of
high (panel d, black arrow) and low (panel d, asterisk) mucin production. Within tumors,
distinct subregions can be seen (panel c) consisting of corded areas that lack signet ring cells
(top) or neoplastic cells floating in mucin pools (bottom) within the same tumor. Tumors
also contain regions composed of solid nodules lacking signet ring cells (Supplementary Fig.
3, “+”); a feature of IDC. However, also within corded areas, some cells were arranged in
single file and contain intracytoplasmic mucin; a feature of ILC (Fig. 5, panel d, red arrow).
Since this low mucin producing region has characteristics of IDC and ILC, we refer to the
solid region as invasive breast carcinoma (IBC). Finally, the mucinous and IBC regions are
separated by bisecting “stroma” (Fig. 5, panel d (+)). However, this stroma is of human
origin because the cells fluoresce green (Fig. 5, panels e and f) and only BCK4 cells express
the ZsGreen tag. Taken together, the pathological data are indicative of an invasive
mucinous carcinoma [56].
The MBCPure of control (placebo) cycling mice and the IBC plus mucinous (MUC) regions
of MBCMixed tumors in E2-treated mice were characterized with the same panel of markers
used for the clinical pulmonary explants and the cell line (Table 1; Fig. 6). ER (brown
nuclei) expression was similar in the mucinous components (MUC) of MBCPure and
MBCMixed, and ER increases in the IBC regions of the MBCMixed (Fig. 6, left column).
Estrogen responsive PR proteins were completely absent in MBCPure, weakly up-regulated
in the MUC region of MBCMixed, and strongly up-regulated in the IBC region of MBCMixed
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suggesting that the IBC component is preferentially stimulated by estrogenic signals (Fig. 6,
middle column). Cytokeratins CK8/18 (epithelial markers, pink) were also up-regulated in
the IBC region of MBCMixed compared to the MUC region and MBCPure tumor (Fig. 6).
Other markers were not remarkably different among regions, except for the neuroendocrine
markers, which were downregulated in the IBC regions of mixed tumors (Table 1). As
expected, the tumors showed high levels of MUC2 staining (brown) in the mucinous regions
but had low to no MUC2 in the IBC region (Fig. 6, right column). Interestingly, the EMT
marker N-cadherin is expressed in the mucinous region of the mixed tumor but is absent in
the IBC region (Table 1). These data suggest the possibility that as previously suggested
[57], in MBCMixed tumors, the IBC subpopulation is derived from mucinous precursors in
response to estrogen signaling.
Whether the IBC is ductal (IDC) or lobular (ILC) could not be histologically determined
since features of both extracellular and intracellular mucin were detectable. We therefore
used molecular markers to discriminate between the two [58]. Loss of E-cadherin and
cytoplasmic localization of p120 catenin characterize ILC [58]. E-cadherin was completely
absent in MBCPure and MBCMixed in both the MUC and IBC regions (Fig. 7). As a positive
control, a tumor derived from the IDC cell line, T47D, showed clear membranous E-
cadherin staining. The absence of E-cadherin in BCK4 tumors suggested that they were
lobular in origin. P120 catenin was expressed in both MBCPure and MBCMixed; however, its
distribution was diffuse and cytoplasmic (Fig. 7), in contrast to the strong membranous
staining of tumors derived from T47D cells. The combination of E-cadherin loss coupled
with the cytoplasmic p120 catenin indicates that both the MBCPure and MBCMixed tumors
originating from BCK4 cells were of lobular origin. While the MBCMixed tumor was called
“invasive breast carcinoma (which can be ILC, IDC or a mixture of both) with mucinous
features” by the reviewing pathologist, molecular analysis shows that the tumor contains
features consistent with ILC. This staining is conserved in the BCK4 cell line. We therefore
conclude that BCK4 cells are models of mucinous disease of lobular origin that will provide
rare insight into the molecular dynamics of such tumors.
Phenotype switching by estrogens—Our data also suggest the possibility that in the
MBCMixed tumors, the ILC component is derived from MBCPure precursors in response to
changed estrogen signaling patterns. To assess this, the proliferation rates of cells in
different morphological regions of BCK4-derived tumors from two control (placebo) and
two estrogen treated (E2) mice were quantified by BrdU incorporation during S-phase (Fig.
8). As expected from their slow growth, only 2 % of cells in the control MBCPure tumors
were undergoing mitosis during the 2 h BrdU pulse. The MUC region of the two MBCMixed
tumors from E2 supplemented mice exhibited an increased (to 5 %) proliferation rate that
was statistically significant (p<0.05). Importantly, in the same mice, same tumors, and same
hormonal environment, proliferation of the ILC regions exceeded 15 % (p<0.001). This
strengthens our conclusion that in MBC, estrogens induce a phenotypic switch to ILC, and
this is accompanied by increased proliferation in tumor subregions. The heterogeneous
regional effects of estrogen within the same tumor are also of interest and have not been
previously described.
3D modeling in vitro—We established a 3D model to recapitulate BCK4 tumor growth in
vitro and to analyze the promotion of the mixed phenotype by estrogen treatment. This
model was also used to ask whether effects of E2 can be blocked by the anti-estrogen
tamoxifen (Tam) or by E2 withdrawal (E2WD). For this, BCK4 cells were grown in a 3D-
matrigel matrix and treated with vehicle (EtOH), E2, or E2 + Tam for 10, 14, or 20 days.
Alternatively, cells were also treated for 7 or 10 days with E2 which was then withdrawn for
3, 4, or 10 days. Signet ring cell quantification was used to assess the mucinous phenotype.
In control conditions, ~30 % of cells were signet ring. Ten to 20 days of E2 halved the
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number of mucin producing cells to ~15 % (Fig. 9a). This effect of E2 was completely
prevented by co-treatment with tamoxifen. On the other hand, E2 treatment for 7 days
followed by 3 days of E2 withdrawal partially restored signet ring cell number suggesting an
initial degree of reversibility. Longer effects of E2 (10 days) were not reversible. We
conclude that E2 effects are mediated directly via ER explaining the efficacy of tamoxifen.
However, once the mixed phenotype is established, it is difficult to reverse. These results
were confirmed in solid BCK4 xenografts (Fig. 9b) grown in the absence or in the presence
of exogenous E2 supplementation. Under control conditions (placebo), the MBCPure tumors
contained ~25 % signet ring cells; similar to the number in the 3D model. In E2 treated
mice, mixed mucinous tumors formed. The MUC component of MBCMixed contained ~15 %
signet ring cells (Fig. 9b) while the ILC component completely lacked signet ring cells.
We conclude that BCK4 cells model human MBC of lobular origin that produce intracellular
and extracellular mucin and contain signet ring cells. However, whether the phenotype is
MBCPure or MBCMixed can be regulated by estrogens. These data highlight the complexity
of MBC; a complexity that we can now model and probe experimentally.
Discussion
Eleven different histologic subtypes of breast cancer have recently been classified based on
gene expression profiling [27]. Included within these are MBC, which are more complex
and heterogeneous than originally anticipated. The molecular data further sub-classified
MBC according to the criteria of Capella et al. [59] into Type A which contain 60–90 %
extracellular mucin and Type B which contain 33–75 % extracellular mucin [59]. Type B
tumors also contain signet ring cells [59]. Cluster analysis of gene expression data placed
Type A and Type B tumors in the luminal centroid [27]; not surprising since MBC are ER
+[26]. What was surprising was that the majority of Type A tumors which are enriched for
extracellular mucin clustered with ILC [27]. In contrast, Type B tumors containing signet
ring cells clustered with neuroendocrine tumors. Both types of MBC differ from IDC NOS,
however [48]. This suggests that all MBC, whether pure or mixed, may be erroneously
categorized as a subtype of IDC if only histological markers such as mucin localization are
considered. Further evidence that MBC differ from IDC NOS is based on the fact that MBC
rarely contain mutations in phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) or v-
akt murine thymoma viral oncogene homolog 1 (AKT1); both of which are commonly
observed in IDC NOS [60].
While reports of ILC that produce extracellular mucin may be rare, three cases have recently
been reported. In all three cases tumors expressed ER and PR, contained intra-cellular and
extracellular mucin, were signet ring cell positive and exhibited loss of E-cadherin [17–19].
Thus more detailed molecular analyses of MBC may reveal that many are of lobular origin
[27] but are currently underestimated because the presence of extracellular mucin is
considered to be a marker of IDC. Expression profiling studies with larger numbers of
MBCPure or MBCMixed have not been done, thus the prevalence of ILC within MBC remains
unknown. One study using tissue arrays examined 40 cases of MBCPure or MBCMixed; all
tumors contained at least some E-cadherin with membranous p120 catenin, which led to
their characterization as IDC [17]. However, some ILC are E-cadherin positive as are some
of the MBC that cluster with them by expression profiling analysis [27]. Thus the presence
of E-cadherin does not rule out that MBC are mixed with ILC. It is clear that more definitive
molecular markers need to be identified for MBCMixed to determine whether the more
invasive regions are IDC or ILC.
The presence of signet ring cells in mucin producing tumors likely signifies that they are of
lobular origin. Signet ring cell carcinomas (SRCC) are classified as a subtype of breast
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cancer. Tumors are classified as such when at least 20 % of the total tumor is composed of
signet ring cells [22, 23, 61]. Mucin producing signet ring cells are present in ILC [5, 20, 22]
and MBC [59] leading many to conclude that SRCC is a variant of ILC [23, 61, 62] but two
studies suggest that SRCC are entities distinct from MBC and ILC [24, 63]. However, three
lines of evidence suggest that signet ring cells are of lobular origin (1) the majority of SRCC
are negative for E-cadherin [64], (2) signet ring cells contain intracellular mucin, and 3)
SRCC metastasize to serosal surfaces [23] resembling the metastatic pattern for ILC. This is
clinically important because the percentage of signet ring cells within tumors can determine
the propensity for recurrence. Patients with stage I breast cancer whose tumors contain as
few as 10 % signet ring cells have an increased risk of recurrence compared to patients
whose tumors have lower numbers of signet ring cells [22].
The ductal or lobular origins of MBCPure and MBCMixed have been unclear to date. Since
the lumen of ductal carcinomas in situ (DCIS) often contain mucin [39], some speculate that
MBCPure originates from DCIS [30]. Others speculate based on loss of heterozygosity
analysis that MBCPure originate from IDC [30]. However, since mucin production is also
associated with lobular carcinoma in situ [65], it is entirely possible that MBCPure are
derived from lobular precursors. While both IDC and ILC originate in the terminal ductal
lobular unit of the breast, they likely arise via different pathways [66]. This is reinforced by
the fact that ILC lack basal cytokeratins such as CK5 are commonly observed in IDC [67].
Expression profiling studies contrasting ILC from IDC [10–13] show that many functional
pathways, including ones involved in immune responses, cell adhesion and motility, and
lipid/fatty acid transport and metabolism differ between the two. However, only
downregulation of the gene encoding E-cadherin (CDH1) in ILC was common among them.
Of note is the loss of E-cadherin expression in the BCK4 cells which correlates with
translocations in chromosome 16 of their karyotype (Fig. 2). Loss of heterozygosity at
chromosome 16 which disrupts the CDH1 gene is common among ILC [68]. As supported
by the data of Weigelt et al. [27], our model suggests that some MBCPure are inherently
lobular and that in MBCMixed, the ILC subpopulation can be derived from MBCPure under
conditions that may involve estrogen signaling. This requires further study, as does the role
of the mesenchymal-like fibroblastic cells in MBCMixed, apparently also of BCK4 origin,
located in stromal-like bands separating MUC regions from ILC regions in our estrogenized
tumors (Fig. 5). Similar bisecting stroma is observed in MBC of patients [56] and in ILC,
giving us confidence in the power of BCK4 cells as investigative tools.
MBC tends to be a disease of older women. The prevalence of MBCPure is ~7 % in women
older than 75 years (median age 71 [69]) and ~1 % in women less than 35 years [25].
Similarly, patients with MBCPure tend to be older (median age 55) than patients with
MBCMixed (median age 47) or IDC NOS [26, 34, 35, 70, 71]. Explanations for this
remarkable difference are unclear but our data suggest that steroid hormones are involved.
One study that analyzed the role of postmenopausal hormone replacement therapy on breast
cancer risk by histologic type reported a non-significant trend for increased MBC in current
estrogen users compared to never users. Interestingly, there was a trend for decreased MBC
in current combined estrogen plus progestin users [72]. Furthermore in postmenopausal
women, endogenous estrogen is largely unopposed by PR while both estrogen and PR are
present in premenopausal women. The presence of PR may explain the low prevalence of
MBC in premenopausal women. The hypothesis that progestins, unlike the case for more
common breast cancer types, are protective against MBC development in premenopausal
women can be studied using the BCK4 model.
With regard to ER, no significant differences in ER status have been reported between
MBCPure and MBCMixed [34], or in the immunohistochemical pattern of ER expression in
mucinous compared to invasive regions of MBCMixed [73]. However, in line with our data
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(Table 1) MBCMixed tend to have higher ER levels than MBCPure as measured
biochemically [73]. Also of interest is the increased expression of PR in the more aggressive
and proliferative ILC tumor regions. High PR expression typically correlates with a more
“differentiated” phenotype and a better prognosis in breast tumors. The infiltrating regions
of MBCMixed are more proliferative than the mucinous regions [38] and proliferation is
generally higher in MBCMixed than in MBCPure [33]. Our studies confirm this (Fig. 8).
The standard of care for MBCPure, like most of the other uncommon histologic subtypes, is
not differentiated from the overall management of breast cancer. Increased understanding of
the role of tumor biology, which we have shown can be influenced by histologic subtype in
the case of MBC, is changing the treatment landscape. Clinically validated genomic tools for
determining the appropriate use of chemotherapy in early stage disease and multiple reports
on the differential responsiveness to available therapies by tumor biologic characteristics are
now available (reviewed in [74]). However, some of these tests may not be reliable for rare
histological subtypes because of the presence of inflammatory cells and/or stroma within
these tumors [75]. Thus, despite these gains in knowledge for breast cancer overall, the
ability to “personalize” treatment decision making in rarer histologic subtypes remains a
research goal. Our unique cell line and its demonstrated plasticity in the face of estrogens
suggests that it may be important to elucidate differences between MBC mixed with IDC or
ILC as a histologic means of predicting for different therapeutic responses and long-term
outcomes. The prognostic and predictive differences between ILC and IDC have been
recently reviewed and are not always consistent [76]. We hypothesize that tumor plasticity
and mixed subcomponents may influence these clinical results and deserve further study.
The postmenopausal patient in our study was given 6 cycles of cyclophosphamide,
doxorubicin, and 5FU followed by radiation and 5 years of tamoxifen. Three years later
metastatic disease recurred as a pleural effusion. Using cells derived from the pleural
effusion we developed a cell line that forms a MBCPure in mice exposed to cycling
estrogens, but switches to MBCMixed with ILC subpopulations when exposed to continuous
physiologic estrogens (Fig. 4). Our BCK4 tumors, like their clinical MBC counterparts [77]
co-express AR along with ER and PR (Supplementary Fig. 2) and may be stimulated to
grow by ARs (Fig. 3). Given the diversity of anti-endocrine therapies available, including
selective ER modulators, a pure ER downregulator and aromatase inhibitors, it is of clinical
interest to determine if histologic aspects of MBC, such as their mucinous components and/
or biologic aspects like AR expression, influence responses to different hormonal therapies.
Moreover, while optimal treatment regimens for patients with MBC remain unclear, BCK4
cells may provide excellent models to study existing and potential novel therapeutic
interventions.
Survival of patients with MBCPure is better than that of patients with MBCMixed [32, 47, 78,
79]; indeed the later has the same prognosis as IDC [26, 30, 69, 80]. Nevertheless, even a
diagnosis of MBCPure may underestimate the risk of eventual (>12 years later) recurrence
[81]. Thus despite its seemingly innocuous local behavior, MBCPure can and does
metastasize [71]. As with other breast cancers, large tumor size (>4 cm) or the presence of
lymph node metastases is associated with decreased survival for either MBCPure or
MBCMixed [35]. The incidence of metastases in MBCMixed (29–72 %) is higher than that of
MBCPure (0–26 %) [32–37] and both MBC types tend to be multifocal [69, 82].
Understanding what may influence the incidence of these unique histologic subtypes and
under-standing which cases merit additional therapy and what the therapeutic targets might
be are important issues. We propose that BCK4 cells are a novel and unique resource to
investigate MBC specifically, and the plasticity of breast cancers in general.
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In summary, MBC is a unique histology that we demonstrate as having plasticity between
ductal and lobular components and highlights the opportunities and challenges of applying
biologic understanding to traditional nomenclature. MBC of lobular origin may be much
more common than originally realized. Furthermore whether MBC are ductal or lobular in
origin cannot be easily discriminated solely on tumor appearance, or even by
immunohistochemistry. The lobular identity of many MBC may require a panel of markers
yet to be identified. We have developed a new human breast cancer cell line that models
mucinous disease, and as xenografts gives rise to pure MBC or MBC mixed with ILC,
depending on the estrogenization state of the mouse. The model recapitulates many aspects
of clinical MBC including their histological appearance, luminal subtype, and protein
marker expression. BCK4 cells are the first model of MBC, specifically those of lobular
subtype. These cells will be useful for indepth studies of hormone regulated growth, MBC
phenotypic plasticity, the biology of mucinous ILC, potential therapeutic interventions, and
pattern of metastatic spread of this poorly understood breast cancer subtype.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Primary breast cancer xenograft tumor contains ER, PR, HER2, CD44, and AR. Breast
cancer cells from a pleural effusion were grown in immunocompromised mice supplemented
with estradiol for 12 weeks. H&E and immunostaining for ER, PR, HER2, CD44, and AR
was performed as described
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The BCK4 cell line exhibits a nearly normal karyotype. A xenograft tumor as grown in Fig.
1 was mechanically dispersed, cultured, and a permanent cell line, BCK4 was established.
Spectral karyotyping of BCK4 cells was performed as described. Each chromosome has a
unique color designation. The karyotype of the cells is 47,XX,del(1)(?p31;?q12),del(7)
(q22),der(8)t(8;11)(p11;q13), 11,der(16)t(1;16) (q12;q11.2)×2,+17
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AR, PR, and ER are functional, regulate endogenous genes and growth of BCK4 cells. a
Transcription assays were performed with exogenous reporter constructs containing
progesterone response elements (PRE2) or estrogen response elements (ERE2) as described.
Cells were treated with vehicle (open bars) or hormone (solid bars) with the progestins
R5020 or MPA, the glucocorticoid dexamethasone (DEX), the androgen R1881, or estradiol
(E2). b Semi-quantitative PCR of BCK4 cells treated with vehicle (Et; EtOH) progestin (R5;
R5020), androgen (R18; R1881), and glucocorticoid (Dex; Dexamethasone). Responsive
genes were assayed at two different timepoints of hormone treatment, 6 or 24 h. Two
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different doses of Dex were used, 100 and 1,000 nM. GAPDH was used as an internal
control. Semi-quantitative PCR analysis of BCK4 cells treated with vehicle (Et; EtOH) or
estrogen (E2) for 6 or 24 h. Two estrogen responsive genes, pS2 and CathD were measured.
GAPDH was used as a loading control. c MTS cell proliferation assay of BCK4 cells treated
with vehicle (EtOH), estradiol (E2), androgen (R1881), progestin (R5020), or the progestin/
androgen (MPA). Cells were assayed at 0, 72, 144, and 192 h of treatment
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BCK4 cells are tumorigenic; estrogen causes a histologic switch. Images of whole tumors,
grown in placebo (left MBCPure) or estrogen (E2, right MBCMixed) supplemented mice,
stained with mucicarmine. Arrow denotes invasive breast carcinoma (IBC) component and
arrowheads mucinous regions (MUC). Red arrow denotes stroma bisecting the IBC and
MUC regions of the MBCMixed tumor
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Estrogen induces regions of mucinous and invasive breast carcinoma; bisecting region is
composed of human tumor cells. ×20 images of a H&E stain and b mucicarmine stain of
MBCPure tumor from placebo supplemented mouse (yellow and black arrows designate
intracellular and extracellular mucin, respectively); c H&E and d mucicarmine stains of
MBCMixed tumor from E2 supplemented mouse (black arrow mucinous region; asterisk
invasive breast carcinoma (IBC) region; plus region bisecting mucinous and IBC; red arrow
cell containing intracytoplasmic mucin); e ×10 ZsGreen stain of bisecting tumor region of
E2 supplemented mouse and f ×40 ZsGreen image of bisecting tumor region
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Estrogen induces regions of invasive breast carcinoma with increased ER and PR and
decreased Muc2 expression. Immunohistochemistry was performed using antibodies
directed IHC against ER, PR, or Muc2 (DAB, brown) CK8/18, CK18 (AP, Permanent red).
Stains of MBCPure tumor and MBCMixed tumor with mucinous (MUC) and invasive breast
carcinoma (IBC) regions are shown
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BCK4 tumors display lobular features. BCK4 tumors were stained with E-cadherin (Ecadh)
or p120 catenin (p120). Staining of pure mucinous tumor (MBCPure) and mixed mucinous
tumor (MBCMixed) mucinous region (MUC) and invasive regions (IBC) are shown (×100).
A T47D tumor is shown as a control for membranous staining of both proteins
Jambal et al. Page 26











Estrogen preferentially stimulates growth of ILC in mixed tumors. BrdU incorporation of
tumors from placebo and E2 supplemented mice. Pure mucinous tumor (MBCPure) and
mixed mucinous tumor (MBCMixed) showing mucinous region (MUC) and invasive lobular
carcinoma (ILC). Five fields were quantified for each tumor and statistical significance was
determined by an unpaired two tailed t test. *p < 0.014 for tumor 1 or tumor 2 MBCPure
versus MBCMixed MUC region of tumor 3 or tumor 4; +p < 0.001 for tumor 3 or tumor 4
ILC versus tumor 1 or tumor 2 MBCPure; #p < 0.001 for tumor 3 or tumor 4 MUC region
versus tumor 3 or tumor 4 ILC region
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Long-term E2 causes signet ring cell loss. a 3D Matrigel cultures of BCK4 cells were
treated 7–20 days with vehicle, E2 alone, or E2 plus tamoxifen (Tam). In one set of 7 or 10
day E2 treated colonies, E2 was withdrawn (E2WD) for 3 to 10 days. Five fields were
quantified for each sample. Signet ring cells were quantified as the percent of total cells. * p
< 0.05; **p < 0.01; ***p < 0.001. b BCK4 tumor xenografts, MBCPure and the MUC and
ILC regions of MBCMixed, were assayed for signet ring cells. Five fields were quantified per
tumor
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